Zimbabwe has turned down a significant American health deal worth $367m (£272m) over five years due to the United States' request for sensitive data.
This rejection was revealed following a government memo from December was leaked, which showed President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesperson has since clarified that the US was demanding access to genetic material for research and profit but refused to share the resulting advantages from future medical innovations.
"We will now turn to the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more talks to secure a agreement agreeable to both sides so the country's critical HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision comes after a similar situation in Kenya, where a high court blocked a related deal with the US after concerns were raised about the security of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing direct bilateral deals to enhance openness and accountability.
Based on reports, 16 African countries have so far agreed to these new health pacts, representing more than $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to share its genetic material and health information over an extended period, with no equivalent assurance of access to any medical innovations – such as new medicines or tests – that could result from that shared data," he stated.
"Put simply, our nation would supply the basic resources for medical research with no assurance that the final treatments would be accessible to our people should a new health crisis emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its push of bilateral deals were upending frameworks already set up through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This framework is designed to ensure that when a nation contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing dialogue with our American counterparts on how future collaboration might be structured in a way that honours the independence and interests of each country."
Health Experts Response
A leading public health body expressed it acknowledged the official position, but urged that talks should continue considering much of the nation's Aids initiatives depended on external financing.
"In cases where specific concerns exist, including those involving data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
The situation underscores the complex tensions between receiving crucial foreign assistance and protecting national sovereignty in an ever more data-driven world.